{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:32Z","timestamp":1788961712810,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/objectives: In some cases of concomitant use of direct oral anticoagulants (DOAC) and certain anticancer medications, pharmacokinetic interactions are expected; however, clinical data is scarce. This report reviews the recommendations on the use of DOAC concurrently with anticancer drugs according to different clinical decision support systems and sources, with a focus on discrepancies. Methods: We reviewed the recommendations from the American Heart Association (AHA), European Heart Rhythm Association (EHRA), summary of product characteristics (SPC) in FASS (Swedish medicine information portal), the Swedish clinical decision support system Janusmed, and information from the Food and Drug Administration (FDA) on the concomitant use of apixaban, edoxaban, and rivaroxaban (activated factor X (FXa) inhibitors) and 80 anticancer drugs from 11 categories (240 drug pairs). Results: No warnings of expected pharmacokinetic drug interactions between FXa inhibitors and anticancer drugs were found for 155 drug pairs (65%) across all sources. The remaining 35% of drug pairs were flagged as having possible interactions with FXa inhibitors according to at least one source. Discrepancies in the recommendations from the different sources were reported. The reported discrepancies were, for the most part, associated with different assessments of the mechanism and the extent of pharmacokinetic interactions of each anticancer medication. Also, knowledge sources have different approaches to reporting potential interactions, in some cases reporting clinically relevant strictly pharmacokinetic interactions, whereas others include even patient-specific factors. Conclusions: The lack of clinical data and different recommendations can make clinical decisions on the concomitant use of DOAC and anticancer drugs difficult. Our compilation is meant to assist clinicians in making decisions based on the available evidence, even if it is scarce.<\/jats:p>","DOI":"10.3390\/ph18071044","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T10:46:05Z","timestamp":1752662765000},"page":"1044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources"],"prefix":"10.3390","volume":"18","author":[{"given":"Karolina","family":"Nowinski","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Karolinska University Hospital, SE 14186 Stockholm, Sweden"},{"name":"Department of Laboratory Medicine, Karolinska Institutet, SE 17176 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9069-1903","authenticated-orcid":false,"given":"Roza","family":"Chaireti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Karolinska University Hospital, SE 14186 Stockholm, Sweden"},{"name":"Department of Medicine Solna, Karolinska Institutet, SE 17176 Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, SE 17176 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.lanepe.2023.100786","article-title":"Atrial fibrillation: Epidemiology, screening and digital health","volume":"37","author":"Linz","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","article-title":"Age and cancer risk: A potentially modifiable relationship","volume":"46","author":"White","year":"2014","journal-title":"Am. J. Prev. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/bcp.15785","article-title":"Pharmacokinetic drug\u2013drug interactions with direct anticoagulants in the management of cancer-associated thrombosis","volume":"89","author":"Vanassche","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdz137","article-title":"Interactions between direct anticoagulants and chemotherapy","volume":"30","author":"Sorigue","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cncr.34642","article-title":"Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer","volume":"129","author":"Mohamed","year":"2023","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_15","first-page":"194","article-title":"Pharmacogenomics and personalized medicine","volume":"1","author":"Adams","year":"2008","journal-title":"Nat. Educ."},{"key":"ref_16","unstructured":"(2025, May 12). Janusmed Interaktioner Och Riskprofil. (In Swedish)."},{"key":"ref_17","unstructured":"FASS (2025, May 12). (In Swedish)."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcpt.13843","article-title":"Interaction alerts: A comparison of classifications and recommendations for clinical management between Janusmed and three other knowledge resources","volume":"132","author":"Tukukino","year":"2023","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"ref_19","unstructured":"FDA (2025, May 12). Available online: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bogaard, L., Tsoi, K., van de Steeg, B., Brandon, E.F.A., Geers, L., van Herwaarden, M., Jansman, F., Maas, D., Monster-Simons, M., and Ong, D.S.Y. (2024). A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1412692"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jamia\/ocx010","article-title":"Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support","volume":"24","author":"Fung","year":"2017","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/11532340-000000000-00000","article-title":"Drug-drug interactions in cardiac and cardiothoracic intensive care units","volume":"33","author":"Smithburger","year":"2010","journal-title":"Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.psychres.2019.03.041","article-title":"A comparison of potential psychiatric drug interactions from six drug interaction database programs","volume":"275","author":"Scott","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/fcp.12769","article-title":"Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug\u2013drug interaction mediated by P-glycoprotein","volume":"36","author":"Lafaie","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: A standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.2009-0290","article-title":"Polypharmacy in older adults with cancer","volume":"15","author":"Maggiore","year":"2010","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"(2023). By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 71, 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oliveira, R.F., Oliveira, A.I., Cruz, A.S., Ribeiro, O., Afreixo, V., and Pimentel, F. (2024). Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: Associated factors. BMC Geriatr., 24.","DOI":"10.1186\/s12877-024-05135-6"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S1470-2045(15)00080-7","article-title":"Polypharmacy in patients with advanced cancer and the role of medication discontinuation","volume":"16","author":"LeBlanc","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"vii36","DOI":"10.1093\/annonc\/mdt266","article-title":"Polypharmacy and the management of the older cancer patient","volume":"23","author":"Balducci","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0049-3848(98)00192-3","article-title":"Synthetic Inhibitors of Thrombin and Factor Xa","volume":"93","author":"Hauptmann","year":"1999","journal-title":"Thromb. Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hammar, T., Jons\u00e9n, E., Bj\u00f6rneld, O., Askfors, Y., Andersson, M.L., and Lincke, A. (2024). Potential Adverse Drug Events Identified with Decision Support Algorithms from Janusmed Risk Profile-A Retrospective Population-Based Study in a Swedish Region. Pharmacy, 12.","DOI":"10.3390\/pharmacy12060168"},{"key":"ref_34","unstructured":"(2025, May 12). Janusmed Interaktioner Och Riskprofil. (In Swedish)."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40266-023-01021-9","article-title":"Pharmacological Risk Assessment Among Older Patients with Polypharmacy Using the Clinical Decision Support System Janusmed Risk Profile: A Cross-Sectional Register Study","volume":"40","author":"Petersson","year":"2023","journal-title":"Drugs Aging"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:30Z","timestamp":1760033430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18071044"],"URL":"https:\/\/doi.org\/10.3390\/ph18071044","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}